

Macro Biologics, Inc. to Present 'Amicidins - Guarding the gateways to sepsis' at World AMR Congress 2024

Infection is a progression – best stopped early

CARLSBAD, CALIFORNIA, UNITED STATES, September 3, 2024

/EINPresswire.com/ -- [Macro Biologics](#),

Inc., is proud to attend, sponsor, and present at the World Antimicrobial

Resistance Congress 2024 in

Philadelphia, PA on September 5th and

6th. Macro's CEO & CSO, Michael P. Bevilacqua, MD, PhD, is scheduled to present on the potential use of Macro's investigational products to help protect key gateways, or entry points, against early microbial invasion that can progress to serious local infection and sepsis.

The logo for Macro Biologics, featuring the word "Macro" in a large, bold, black, sans-serif font, and the word "Biologics" in a smaller, blue, sans-serif font below it.

“

This gathering of dedicated, like-minded people in Philadelphia offers an important opportunity to exchange scientific, medical, and operational strategies to address this enormous challenge.”

Michael Bevilacqua, MD, PhD

“Life-threatening infections, including those driven by antimicrobial resistance, continue to plague the world. The WHO estimates that as many as 1 in 5 deaths worldwide are sepsis related,” said Dr. Bevilacqua. “This gathering of dedicated, like-minded people in Philadelphia offers an important opportunity to exchange scientific, medical, and operational strategies to address this enormous challenge. At Macro, we have spent substantial time and resources building a new class of large molecule biologics, called [Amicidins](#), which we think can help.”

Amicidins are Macro's first class of proprietary macro

biologics, purpose-built for local application to vulnerable tissues to help prevent and treat life-threatening infections. Inspired by nature, they combine beneficial physical properties (like barrier to block or surfactant to cleanse) and broad microbicidal activity. Amicidins are active against Gram-positive and Gram-negative bacteria (including antibiotic-resistant strains), as well as *Candida* spp. They are composed of amino acids and designed to be safe for people and the environment.

Using Amicidins, Macro is developing several investigational products designed to protect and cleanse vulnerable tissues, which can serve as gateways to serious infection. Macro's first focus is protecting the wounds of surgery and trauma. Going forward, Macro intends to use Amicidins for innovative products across multiple healthcare sectors, and beyond.

About Macro Biologics:

At Macro Biologics, Inc., we design, patent, and produce large molecule biologics that combine physical and functional properties. Our business is to help industry-leading corporations create new products and improve existing ones – for safer healthcare, clean food & water, and better packaging. Our core principle is progress guided by nature. Macro is headquartered in Carlsbad, CA.

Additional information can be found at www.macrobiologics.com.

Eric Rusaw

Macro Biologics

erusaw@macrobiologics.com

This press release can be viewed online at: <https://www.einpresswire.com/article/739637187>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.